ImmuniMed Inc. is an innovative, clinical-stage, Research & Development Biopharmaceutical Company. ImmuniMed Inc. develops oral antibody therapy using passive vaccination to treat and prevent gastro-enteric infections. Their technology is designed to utilize chicken eggs as bioreactors to manufacture specific polyclonal antibodies – a new class of biopharmaceuticals.
member
Our partner BioTalent Canada has launched the Building Workplace Resiliency resources for its I.D.E.A.L. Biosciences Employer Recognition Program. This program served as a guide for employers seeking to submit fall program applications.
Sign up for one of BAM's newsletter to learn more about bioscience, happenings in Manitoba's bioeconomy, industry conferences, and BAM training events.